NKGen Biotech

NKGen Biotech EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of NKGen Biotech (NKGN) as of Nov 22, 2026 is -0.29. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -0.93 — a change of -68.83% (higher).

EV/EBITDA

-0.29

YoY

-68.83%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of NKGen Biotech is 2025 -0.29 . EV/EBITDA (Enterprise Value to EBITDA) of NKGen Biotech was 2024 -0.93 . It decreases by -68.83% higher compared to the previous year.

The NKGen Biotech EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2021
-2.72 USD
Jan 1, 2022
-0.81 USD
Jan 1, 2023
-0.93 USD
Jan 1, 2025
-0.29 USD
The NKGen Biotech EV/EBITDA history
YEAREV/EBITDAYoY
-0.29-68.83%
-0.93+14.90%
-0.81-70.17%
-2.72—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NKGen Biotech Stock analysis

What does NKGen Biotech do? NKGen Biotech Inc develops autologous and allogeneic NK cell therapies for neurodegenerative and oncological diseases using its SuperNK platform. The company commercializes SNK01 for neurodegenerative diseases and SNK02 for cancer through clinical trials. Autologous NK cell immunotherapy involves harvesting pure NK cells from patients, activating them, and reinfusing them to enhance immune function and eliminate abnormal cells. The company focuses on treating cancer and neurodegenerative conditions with its SNK platform therapies. NKGen Biotech Inc's revenue model is based on conducting clinical trials for SNK01 and SNK02, with potential future commercialization of these therapies. The company is clinical-stage, meaning it generates income through research and development funding rather than product sales. Its primary focus is on developing therapies for cancer and neurodegenerative diseases using autologous and allogeneic NK cell approaches. The company's SNK platform enables the development of therapies that use pure NK cells harvested from patients' blood, activated, and reinfused to improve immune system function. This approach targets cancer, autoimmune, and neurodegenerative diseases. NKGen Biotech Inc's business model centers on advancing these therapies through clinical trials to reach commercialization stage. NKGen Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NKGen Biotech stock

EV/EBITDA (Enterprise Value to EBITDA) of NKGen Biotech is -0.29 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of NKGen Biotech changed from -0.93 to -0.29, representing a -68.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) NKGen Biotech since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s NKGen Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — NKGen Biotech

All Key Metrics — NKGen Biotech